JP2020511450A - ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のためのデスメチルアネトールトリチオン誘導体 - Google Patents

ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のためのデスメチルアネトールトリチオン誘導体 Download PDF

Info

Publication number
JP2020511450A
JP2020511450A JP2019548696A JP2019548696A JP2020511450A JP 2020511450 A JP2020511450 A JP 2020511450A JP 2019548696 A JP2019548696 A JP 2019548696A JP 2019548696 A JP2019548696 A JP 2019548696A JP 2020511450 A JP2020511450 A JP 2020511450A
Authority
JP
Japan
Prior art keywords
day
compound
mitochondrial
iia
ros
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019548696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511450A5 (enExample
Inventor
ディオレズ，フィリップ
マリン，フレデリック
プチジャン，オリバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority claimed from PCT/EP2018/055651 external-priority patent/WO2018162581A1/en
Publication of JP2020511450A publication Critical patent/JP2020511450A/ja
Publication of JP2020511450A5 publication Critical patent/JP2020511450A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2019548696A 2017-03-07 2018-03-07 ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のためのデスメチルアネトールトリチオン誘導体 Pending JP2020511450A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762467874P 2017-03-07 2017-03-07
EP17159691 2017-03-07
US62/467,874 2017-03-07
EP17159691.9 2017-03-07
PCT/EP2018/055651 WO2018162581A1 (en) 2017-03-07 2018-03-07 Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production

Publications (2)

Publication Number Publication Date
JP2020511450A true JP2020511450A (ja) 2020-04-16
JP2020511450A5 JP2020511450A5 (enExample) 2021-04-15

Family

ID=61628329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019548696A Pending JP2020511450A (ja) 2017-03-07 2018-03-07 ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のためのデスメチルアネトールトリチオン誘導体

Country Status (10)

Country Link
US (1) US11484529B2 (enExample)
EP (1) EP3592348A1 (enExample)
JP (1) JP2020511450A (enExample)
KR (1) KR20190129900A (enExample)
CN (1) CN110662535A (enExample)
AU (1) AU2018232799B2 (enExample)
BR (1) BR112019018495A2 (enExample)
CA (1) CA3055122A1 (enExample)
IL (1) IL269127A (enExample)
RU (1) RU2019131478A (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554184A (ja) * 2020-12-10 2023-12-26 マリン，フレデリク 虚血再灌流傷害の予防又は治療のためのアネトールトリチオン投与治療計画
JP2024506053A (ja) * 2021-02-09 2024-02-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 複合体ｉの制御剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113038969A (zh) * 2018-09-06 2021-06-25 Op2药品公司 包含茴三硫或其衍生物的环糊精复合物的药物组合物
CN112546216B (zh) * 2020-11-20 2022-10-28 西湖大学 小分子化合物奥替普拉在制备增强体液免疫应答的药物中的应用
CN114414332B (zh) * 2022-01-05 2024-04-16 北京科技大学 一种基于Al-CQDs和Al-CNSs的抗氧化剂的制备方法
CN119185368A (zh) * 2024-09-26 2024-12-27 中南大学 具有线粒体序贯靶向能力的强抗氧化性纳米药物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2001091118A1 (fr) * 2000-05-22 2001-11-29 Clarion Co., Ltd. Lecteur de disque
CN1355156A (zh) * 2000-11-27 2002-06-26 朱国和 含有造纸废料污泥的微生物菌肥及其制备方法
CN102961376A (zh) * 2012-11-06 2013-03-13 暨南大学 HMG-CoA还原酶抑制剂氟伐他汀在制备抗淋巴瘤药物中的应用
EP2889294A1 (en) * 2012-08-21 2015-07-01 Soochow University 3h-1,2-dithiocyclopentene-3-thioketone compounds and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
KR20030067935A (ko) 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
CN1244325C (zh) 2001-05-11 2006-03-08 成都国嘉联合制药有限公司 胆维他在制药中的应用
US7199122B2 (en) 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
US20050182128A1 (en) 2002-02-13 2005-08-18 Stephen Lam Use of anethole dithiolethione in lung cancer chemoprevention
TW200640898A (en) 2005-02-24 2006-12-01 Solvay Pharm Bv Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
EP2125775A4 (en) 2007-03-01 2011-07-13 Cedars Sinai Medical Center ANTIOXIDATION POLYMERS WITH [1,2] -DITHIOLANTEILES AND THEIR USE
CN102961375B (zh) 2012-12-05 2015-01-14 苏州大学 一种ampk激活剂及其在制备治疗糖尿病和/或糖尿病并发症的药物中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2001091118A1 (fr) * 2000-05-22 2001-11-29 Clarion Co., Ltd. Lecteur de disque
CN1355156A (zh) * 2000-11-27 2002-06-26 朱国和 含有造纸废料污泥的微生物菌肥及其制备方法
EP2889294A1 (en) * 2012-08-21 2015-07-01 Soochow University 3h-1,2-dithiocyclopentene-3-thioketone compounds and application thereof
CN102961376A (zh) * 2012-11-06 2013-03-13 暨南大学 HMG-CoA还原酶抑制剂氟伐他汀在制备抗淋巴瘤药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROWN, DENNIS A.; ET AL: "Synthesis and structure-activity relationships study of dithiolethiones as inducers of glutathione i", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24(24),, JPN7022000503, 2014, pages 5829 - 5831, ISSN: 0004701579 *
MARIA N. VIANA; ET AL: "Recherche de proprietes antibilharziennesede dithiole-thiones, d'intermediaires", EUROPEAN JOURANAL MEDICINAL CHEMISTRY-CHIMI THERAPEUTIQUE, vol. 21(2),, JPN7022000504, 1986, pages 123 - 130, ISSN: 0004701580 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554184A (ja) * 2020-12-10 2023-12-26 マリン，フレデリク 虚血再灌流傷害の予防又は治療のためのアネトールトリチオン投与治療計画
JP2024506053A (ja) * 2021-02-09 2024-02-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 複合体ｉの制御剤

Also Published As

Publication number Publication date
KR20190129900A (ko) 2019-11-20
AU2018232799A1 (en) 2019-10-03
US11484529B2 (en) 2022-11-01
US20210154175A1 (en) 2021-05-27
AU2018232799B2 (en) 2021-11-25
IL269127A (en) 2019-11-28
BR112019018495A2 (pt) 2020-04-14
CN110662535A (zh) 2020-01-07
EP3592348A1 (en) 2020-01-15
RU2019131478A (ru) 2021-04-07
RU2019131478A3 (enExample) 2021-07-09
CA3055122A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
US11318113B2 (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
US11484529B2 (en) Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
KR102664994B1 (ko) 중수소화 화합물 및 이의 용도
US20200062712A1 (en) Aldehyde trapping compounds and uses thereof
US9192610B2 (en) Use of quinazoline derivatives for neurodegenerative diseases
WO2018162581A1 (en) Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
CN113347972B (zh) 治疗线粒体功能障碍的方法和制剂
BR112021003997A2 (pt) composição farmacêutica compreendendo complexos de ciclodextrina de anetol tritiona ou derivados da mesma
JP2016536350A (ja) キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法
WO2017216792A1 (en) Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
JPWO2003031414A1 (ja) 新規なヘテロ環化合物および抗炎症薬
US10653668B2 (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
WO2019108673A1 (en) Compounds for treating near vision disorders
WO2010039260A2 (en) Spiperone derivatives and methods of treating disorders
RU2775597C2 (ru) Ингибитор продукции реактивных форм кислорода для лечения заболеваний, связанных со свободными радикалами кислорода
MX2011006434A (es) Derivados de arilciclopropilacetamida utiles como activadores de glucocinasa.
JPWO2003000668A1 (ja) オキサ（チア）ゾリジン化合物、製造法および抗炎症薬
WO2007125720A1 (ja) 分子シャペロン発現誘導剤
BR112015016433B1 (pt) Uso de um composto de formula (i) para tratar um disturbio associado com a tensão do dobramento incorreto da proteína

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230606